The role of MEOX1 in non-neoplastic and neoplastic diseases - 13/01/23
Abstract |
Targeted gene therapy has shown durable efficacy in non-neoplastic and neoplastic patients. Therefore, finding a suitable target has become a key area of research. Mesenchyme homeobox 1 (MEOX1) is a transcriptional factor that plays a significant role in regulation of somite development. Evidence indicates that abnormalities in MEOX1 expression and function are associated with a variety of pathologies, including non-neoplastic and neoplastic diseases. MEOX1 expression is upregulated during progression of most diseases and plays a critical role in maintenance of the cellular phenotypes such as cell differentiation, cell cycle arrest and senescence, migration, and proliferation. Therefore, MEOX1 may become an important molecular target and therapeutic target. This review will discuss the current state of knowledge on the role of MEOX1 in different diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | MEOX1 is homologous domain transcription factor and plays an important role in cellular development and differentiation. |
• | MEOX1 is first identified in fibrosis and involve in the progression. |
• | MEOX1 is expressed in a variety of neoplastic diseases and is associated with tumor cell growth and metastasis. |
• | Inhibition of MEOX1 can inhibit the progression of related diseases and may be a molecular target for disease treatment. |
Abbreviations : MEOX1, HSCs, hMSCs, UTR, PAX3, KFS, CCNB1, VSMCs, RhoA, CDC42, CXCR4, SDF-1α, PPARα, CD, TGF-β, TNBC, PTEN, BCSCs, JAK, STAT5B, EMT, TME, OS, PBX1, NSCLC
Keywords : MEOX1, Upregulated gene, Cellular phenotype, Disease progression, Therapeutic target
Plan
Vol 158
Article 114068- février 2023 Retour au numéro
Article précédent
- The biomedical potential of tardigrade proteins: A review
- Nadiia Kasianchuk, Piotr Rzymski, Łukasz Kaczmarek
- Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy
- Gemma Ferrer-Curriu, Carolina Soler-Botija, Sandra Charvatova, Benjamin Motais, Santiago Roura, Carolina Galvez-Monton, Marta Monguió-Tortajada, Oriol Iborra-Egea, Michele Emdin, Josep Lupón, Alberto Aimo, Juli R. Bagó, Antoni Bayés-Genís
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?